Figure 8.

Tissue pharmacokinetics of ¹²⁵I-M616 (left) and ¹¹¹In-M616 (right) after administration of 0.3 mg/kg IV dose in male C57BL/6 mice (n = 3/time point). Quantitation of ¹²⁵I-M616 PK in tissues suggests kidney, lung, and heart are the primary sites of tissue exposure in C57BL/6 mouse. A complementary analysis using ¹¹¹In-M616 confirms the role of the kidney as a site of elevated M616 catabolism based on probe residualization in this organ. Note: both absolute levels (%ID/g) and a shift in t_max for ¹¹¹In-M616 in kidney relative to other tissues indicates specific catabolism.